ARV-806 / Arvinas - LARVOL DELTA

Anticipated Upcoming Milestones and Expectations (GlobeNewswire) - "Share data with global regulatory authorities to potentially support regulatory filings (2Q 2025) and submit new drug application to the U.S. Food and Drug Administration for potential approval (2H 2025); Add a combination cohort of vepdegestrant plus Pfizer’s KAT6 inhibitor (PF-07248144) to Pfizer’s ongoing Phase 1 trial (NCT04606446)....ARV-806: Novel PROTAC KRAS G12D degrader: Initiate a first-in-human Phase 1 trial in patients with solid tumors harboring KRAS G12D mutations (2H 2025)."

FDA filing • Filing • New P1 trial • Trial status • Solid Tumor

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) - "ARV-393: Oral PROTAC BCL6 degrader: Present preclinical data of ARV-393 in combination with standard of care biologic agents and small molecule inhibitors in high grade and aggressive diffuse large B-cell lymphoma in vivo models at the American Association for Cancer Research Annual Meeting (April 25-30, 2025). Disclose preliminary data from the ongoing Phase 1 clinical trial in patients with NHL (ClinicalTrials.gov Identifier: NCT06393738) in 2025....Novel PROTAC KRAS G12D degrader: File an Investigational New Drug (IND) application in 2025."

IND • P1 data • Preclinical • Diffuse Large B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Solid Tumor

Arvinas…Highlights Upcoming Milestones, and Provides Corporate Update (GlobeNewswire) - "ARV-393: Oral PROTAC BCL6 degrader - Present initial data from the ongoing Phase 1 clinical trial in patients with B-cell lymphomas (NCT06393738). Novel PROTAC KRAS G12D degrader: File an Investigational New Drug (IND) application."

IND • P1 data • Non-Hodgkin’s Lymphoma • Oncology

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) - "ARV-393: Oral PROTAC BCL6 degrader - Continue recruiting patients in the first-in-human Phase 1 clinical trial evaluating ARV-393 in patients with B-cell lymphomas. Novel PROTAC KRAS G12D degrader: File an Investigational New Drug (IND) application in 2025."

IND • Trial status • Non-Hodgkin’s Lymphoma